GlassScriptPhysician profile
Karla Yanes
NPI 1659072213
$2,931.40
in general payments reported to CMS, 2019-2025
19 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,245 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,627 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,626.62 |
| Education | $304.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $710.84 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $488.83 | 2024-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $219.83 | 2024-2025 | Zoryve |
| Genzyme Corporation | $205.84 | 2024-2025 | |
| Ucb, INC. | $191.27 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $185.78 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $172.93 | 2025 | |
| Revance Therapeutics, INC. | $147.53 | 2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $117.51 | 2025 | Sotyktu |
| Janssen Biotech, INC. | $99.00 | 2024 | Tremfya |
| Incyte Corporation | $67.69 | 2024-2025 | Opzelura |
| Amgen INC. | $64.66 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $60.98 | 2024-2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.27 | 2024 | Siliq |
| Mayne Pharma Commercial LLC | $46.00 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.25 | 2024 | Cyltezo |
| Leo Pharma INC. | $19.50 | 2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $17.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Yanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.